person · Reporting owner

Fust Matthew K

Disclosed activity across 7 companies

Tapewire entity: 17933
SEC CIK: 0001397266

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Atara Biotherapeutics, Inc.ATRA · Entity 6828	Director	June 09, 2026	June 11, 2026
Electra Therapeutics, Inc.ETRA · Entity 9265	Director	September 18, 2026	September 18, 2026
MACROGENICS INCMGNX · Entity 6104	Director	May 16, 2019	May 20, 2019
Neumora Therapeutics, Inc.NMRA · Entity 6115	Director	May 27, 2026	May 29, 2026
Ultragenyx Pharmaceutical Inc.RARE · Entity 4337	Director	May 14, 2026	May 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Atara Biotherapeutics, Inc.

Report date June 09, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	30,188	Reported balance After 2026-06-09 transaction · row 1 1 source row Row 1 · 2026-06-09 · Grant · Acquired 12,000 · Balance 30,188 F1: These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

Filing footnotes · ownership attribution and instrument terms

F1: These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

Electra Therapeutics, Inc.

Report date September 18, 2026 · Filed September 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 · Expires 2033-11-16	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-18 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: 1/4th of the total shares subject to this option vested one year after October 16, 2023, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.96 · Expires 2036-02-12	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-18 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: 1/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-09-16	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-09-18 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F3: The shares subject to this option shall vest on the earlier of September 17, 2027 and the date of the next annual meeting of the Issuer's stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: 1/4th of the total shares subject to this option vested one year after October 16, 2023, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

F2: 1/48th of the total shares subject to this option shall vest monthly commencing from February 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.

F3: The shares subject to this option shall vest on the earlier of September 17, 2027 and the date of the next annual meeting of the Issuer's stockholders.

MACROGENICS INC

Report date May 16, 2019 · Filed May 20, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2029-05-16	Direct	10,000	Reported balance After 2019-05-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-05-16 · Grant · Acquired 10,000 · Balance 10,000 F1: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

Neumora Therapeutics, Inc.

Report date May 27, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2036-05-26	Direct	80,000	Reported balance After 2026-05-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-27 · Grant · Acquired 80,000 · Balance 80,000 F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026.

Ultragenyx Pharmaceutical Inc.

Report date May 14, 2026 · Filed May 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	33,696	Reported balance After 2026-05-14 transaction · row 1 1 source row Row 1 · 2026-05-14 · Grant · Acquired 7,751 · Balance 33,696 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.80 · Expires 2036-05-14	Direct	14,058	Reported balance After 2026-05-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-14 · Grant · Acquired 14,058 · Balance 14,058 F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

F2: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Crinetics Pharmaceuticals, Inc.

Report date September 01, 2026 · Filed September 01, 2026

Section 16 reporting ended · disclosed 2026-09-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2026-09-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-09-01 · Disposition to issuer · Disposed 22,836 · Balance 5,925 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Row 2 · 2026-09-01 · Disposition to issuer · Disposed 5,925 · Balance 0 F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.91 · Expires 2028-03-16	Direct	Reported balance After 2026-09-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-01 · Disposition to issuer · Disposed 2,092 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.32 · Expires 2033-06-15	Direct	Reported balance After 2026-09-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-09-01 · Disposition to issuer · Disposed 17,500 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.71 · Expires 2034-06-07	Direct	Reported balance After 2026-09-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-09-01 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.33 · Expires 2035-06-11	Direct	Reported balance After 2026-09-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-09-01 · Disposition to issuer · Disposed 10,350 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.87 · Expires 2036-06-18	Direct	Reported balance After 2026-09-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-09-01 · Disposition to issuer · Disposed 9,730 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").

F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding.

F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.

F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.

Dermira, Inc.

Report date February 20, 2020 · Filed February 25, 2020

Section 16 reporting ended · disclosed 2020-02-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-02-20 transaction · row 1 1 source row Row 1 · 2020-02-20 · Disposition to issuer · Disposed 5,051 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51 · Expires 2024-06-05	Direct	Reported balance After 2020-02-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-02-20 · Disposition to issuer · Disposed 14,224 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2025-06-10	Direct	Reported balance After 2020-02-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-02-20 · Disposition to issuer · Disposed 10,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.82 · Expires 2026-06-20	Direct	Reported balance After 2020-02-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-02-20 · Disposition to issuer · Disposed 10,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.01 · Expires 2027-06-12	Direct	Reported balance After 2020-02-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.95 · Expires 2028-06-12	Direct	Reported balance After 2020-02-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.38 · Expires 2029-06-03	Direct	Reported balance After 2020-02-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-02-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-02-20 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.

F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 12, 2021 Filed Jul 13, 2021 21:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	5,000	$20.71	$103,550.00	Disclosure SEC source: 0001209191-21-046554 · doc4.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,536 F2 · kind: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter. F3 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $20.71. The range of sales prices on the transaction date was $20.54 to $21.00 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document
July 12, 2021 Filed Jul 13, 2021 21:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	5,000	$1.91	$9,550.00	Disclosure SEC source: 0001209191-21-046554 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date. Read SEC document
June 24, 2021 Filed Jun 28, 2021 22:24 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	4,125	$0.00 Strike: $93.20	$0.00	Disclosure SEC source: 0001209191-21-043540 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,125 Underlying: Common Stock · 4,125 shares Expires 2031-06-24 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022. Read SEC document
June 24, 2021 Filed Jun 28, 2021 22:24 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	2,145	$0.00	$0.00	Disclosure SEC source: 0001209191-21-043540 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,695 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2022. Read SEC document
June 22, 2021 Filed Jun 23, 2021 21:00 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GrantStock Option (right to buy) · Derivative	17,500	$0.00 Strike: $20.23	$0.00	Disclosure SEC source: 0001209191-21-042765 · doc4.xml · derivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-06-21 F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document
June 08, 2021 Filed Jun 9, 2021 23:05 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	17,500	$0.00 Strike: $13.80	$0.00	Disclosure SEC source: 0001140361-21-020432 · form4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-06-07 F2 · derivative.exercise_date: The option shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document
June 08, 2021 Filed Jun 9, 2021 23:05 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantCommon Stock	11,000	$0.00	$0.00	Disclosure SEC source: 0001140361-21-020432 · form4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,854 F1 · shares: These restricted stock units shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document
July 06, 2020 Filed Jul 8, 2020 16:30 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Exercise / conversionStock Option (Right to Buy) · Derivative	6,181	$0.00 Strike: $21.00	$0.00	Disclosure SEC source: 0001209191-20-041644 · doc4.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,181 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested with respect to 1/36th of the shares monthly from the grant date of January 29, 2014 such that option fully vested on the third anniversary of the grant date. Read SEC document
July 06, 2020 Filed Jul 8, 2020 16:30 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	6,181	$90.00	$556,290.00	Disclosure SEC source: 0001209191-20-041644 · doc4.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,550 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
July 06, 2020 Filed Jul 8, 2020 16:30 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Exercise / conversionCommon Stock	6,181	$21.00	$129,801.00	Disclosure SEC source: 0001209191-20-041644 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 01, 2020 Filed Jul 6, 2020 18:21 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Exercise / conversionStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $21.00	$0.00	Disclosure SEC source: 0001209191-20-040945 · doc4.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,181 Underlying: Common Stock · 5,000 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested with respect to 1/36th of the shares monthly from the grant date of January 29, 2014 such that the option fully vested on the third anniversary of the grant date. Read SEC document
July 01, 2020 Filed Jul 6, 2020 18:21 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	5,000	$85.00	$425,000.00	Disclosure SEC source: 0001209191-20-040945 · doc4.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,550 F1 · kind: The exercise and sale reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
July 01, 2020 Filed Jul 6, 2020 18:21 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Exercise / conversionCommon Stock	5,000	$21.00	$105,000.00	Disclosure SEC source: 0001209191-20-040945 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 26, 2020 Filed Jun 30, 2020 17:12 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	4,250	$0.00 Strike: $76.58	$0.00	Disclosure SEC source: 0001209191-20-039406 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires 2030-06-26 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 26, 2021. Read SEC document
June 26, 2020 Filed Jun 30, 2020 17:12 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	2,550	$0.00	$0.00	Disclosure SEC source: 0001209191-20-039406 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,550 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 26, 2021 Read SEC document
June 19, 2020 Filed Jun 22, 2020 20:24 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $23.23	$0.00	Disclosure SEC source: 0001209191-20-038179 · doc4.xml · derivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2030-06-18 F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document
June 16, 2020 Filed Jun 17, 2020 21:45 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	24,500	$0.00 Strike: $10.54	$0.00	Disclosure SEC source: 0001209191-20-037366 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Underlying: Common Stock · 24,500 shares Expires 2030-06-15 F2 · derivative.exercise_date: The option shall vest on the earlier of June 16, 2021 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document
June 16, 2020 Filed Jun 17, 2020 21:45 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantCommon Stock	8,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-037366 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,854 F1 · shares: These restricted stock units shall vest on the earlier of June 16, 2021 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document
May 18, 2020 Filed May 19, 2020 23:13 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	1,875	$75.00	$140,625.00	Disclosure SEC source: 0001209191-20-030709 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
April 22, 2020 Filed Apr 24, 2020 17:00 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	1,875	$65.00	$121,875.00	Disclosure SEC source: 0001209191-20-025550 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,875 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:32 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerRestricted Stock Unit · Derivative	3,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-20-001625 · primarydocument.xml · derivative · entry 8 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:32 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerDirector Stock Option (right to buy) · Derivative	6,000	Not disclosed Strike: $9.38	Not disclosed	Disclosure SEC source: 0001562180-20-001625 · primarydocument.xml · derivative · entry 7 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2029-06-03 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:32 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerDirector Stock Option (right to buy) · Derivative	6,000	Not disclosed Strike: $9.95	Not disclosed	Disclosure SEC source: 0001562180-20-001625 · primarydocument.xml · derivative · entry 6 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2028-06-12 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:32 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerDirector Stock Option (right to buy) · Derivative	6,000	Not disclosed Strike: $28.01	Not disclosed	Disclosure SEC source: 0001562180-20-001625 · primarydocument.xml · derivative · entry 5 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2027-06-12 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:32 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerDirector Stock Option (right to buy) · Derivative	10,344	Not disclosed Strike: $28.82	Not disclosed	Disclosure SEC source: 0001562180-20-001625 · primarydocument.xml · derivative · entry 4 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,344 shares Expires 2026-06-20 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:32 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerDirector Stock Option (right to buy) · Derivative	10,344	Not disclosed Strike: $16.00	Not disclosed	Disclosure SEC source: 0001562180-20-001625 · primarydocument.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,344 shares Expires 2025-06-10 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:32 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerDirector Stock Option (right to buy) · Derivative	14,224	Not disclosed Strike: $5.51	Not disclosed	Disclosure SEC source: 0001562180-20-001625 · primarydocument.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,224 shares Expires 2024-06-05 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. Read SEC document
February 20, 2020 Filed Feb 25, 2020 00:32 UTC	Dermira, Inc. DERM · Entity 11896	Disposition to issuerCommon Stock	5,051	$18.75	$94,706.25	Disclosure SEC source: 0001562180-20-001625 · primarydocument.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. Read SEC document
December 24, 2019 Filed Dec 26, 2019 21:13 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	3,000	$15.00	$45,000.00	Disclosure SEC source: 0001562180-19-006267 · primarydocument.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,051 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
December 16, 2019 Filed Dec 18, 2019 23:32 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative	3,500	$0.00 Strike: $1.91	$0.00	Disclosure SEC source: 0001209191-19-061184 · doc4.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,092 Underlying: Common stock · 3,500 shares Expires 2028-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 90 days prior to the trading date. F2 · derivative.exercise_date: Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter. Read SEC document
December 16, 2019 Filed Dec 18, 2019 23:32 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	SaleCommon Stock	3,500	$22.50	$78,750.00	Disclosure SEC source: 0001209191-19-061184 · doc4.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,536 F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 90 days prior to the trading date. Read SEC document
December 16, 2019 Filed Dec 18, 2019 23:32 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	Exercise / conversionCommon Stock	3,500	$1.91	$6,685.00	Disclosure SEC source: 0001209191-19-061184 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 90 days prior to the trading date. Read SEC document
December 12, 2019 Filed Dec 13, 2019 22:13 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	3,000	$12.00	$36,000.00	Disclosure SEC source: 0001562180-19-006079 · primarydocument.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,051 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
September 12, 2019 Filed Sep 16, 2019 20:09 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	6,000	$8.77	$52,636.20	Disclosure SEC source: 0001562180-19-004818 · primarydocument.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,051 F1 · price: This transaction was executed in multiple trades at prices ranging from $8.76 to $8.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 27, 2019 Filed Jul 1, 2019 21:00 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $20.25	$0.00	Disclosure SEC source: 0001209191-19-039765 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-26 F2 · derivative.exercise_date: The option shall vest on the earlier of June 27, 2020 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document
June 27, 2019 Filed Jul 1, 2019 21:00 UTC	Atara Biotherapeutics, Inc. ATRA · Entity 6828	GrantCommon Stock	4,000	$0.00	$0.00	Disclosure SEC source: 0001209191-19-039765 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,854 F1 · shares: These restricted stock units shall vest on the earlier of June 27, 2020 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document
June 21, 2019 Filed Jun 25, 2019 20:09 UTC	Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $23.24	$0.00	Disclosure SEC source: 0001209191-19-038897 · doc4.xml · derivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-06-20 F1 · derivative.exercise_date: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document
June 12, 2019 Filed Jun 14, 2019 21:16 UTC	Dermira, Inc. DERM · Entity 11896	Exercise / conversionCommon Stock · Derivative	3,000	$0.00	$0.00	Disclosure SEC source: 0001562180-19-003532 · primarydocument.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F2 · derivative.exercise_date: The RSU, which was granted on June 12, 2018, fully vested on June 12, 2019. F1 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document
June 12, 2019 Filed Jun 14, 2019 21:16 UTC	Dermira, Inc. DERM · Entity 11896	Exercise / conversionCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001562180-19-003532 · primarydocument.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 11, 2019 Filed Jun 13, 2019 20:44 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $58.74	$0.00	Disclosure SEC source: 0001209191-19-036811 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-06-11 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 11, 2020. Read SEC document
June 11, 2019 Filed Jun 13, 2019 20:44 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001209191-19-036811 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,750 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 11, 2020. Read SEC document
June 04, 2019 Filed Jun 7, 2019 00:15 UTC	Dermira, Inc. DERM · Entity 11896	GrantRestricted Stock Unit · Derivative	3,000	$0.00	$0.00	Disclosure SEC source: 0001562180-19-003402 · primarydocument.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F3 · derivative.exercise_date: The RSU will vest 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document
June 04, 2019 Filed Jun 7, 2019 00:15 UTC	Dermira, Inc. DERM · Entity 11896	GrantDirector Stock Option (right to buy) · Derivative	6,000	$0.00 Strike: $9.38	$0.00	Disclosure SEC source: 0001562180-19-003402 · primarydocument.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-06-03 F1 · derivative.exercise_date: The stock option will vest and become exercisable as to 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date. Read SEC document
May 16, 2019 Filed May 20, 2019 21:47 UTC	MACROGENICS INC MGNX · Entity 6104	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001125345-19-000072 · wf-form4_155838884018358.xml · derivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant. Read SEC document
February 06, 2019 Filed Feb 8, 2019 22:41 UTC	MACROGENICS INC MGNX · Entity 6104	Exercise / conversionStock Option (right to buy) · Derivative	6,924	$0.00 Strike: $20.15	$0.00	Disclosure SEC source: 0001125345-19-000018 · wf-form4_154966566940123.xml · derivative · entry 3 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,924 shares Expires 2024-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 06, 2019 Filed Feb 8, 2019 22:41 UTC	MACROGENICS INC MGNX · Entity 6104	SaleCommon Stock	6,924	$29.38	$203,427.12	Disclosure SEC source: 0001125345-19-000018 · wf-form4_154966566940123.xml · nonDerivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 30, 2018. F2 · price: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $29.23 to $29.73. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range. Read SEC document
February 06, 2019 Filed Feb 8, 2019 22:41 UTC	MACROGENICS INC MGNX · Entity 6104	Exercise / conversionCommon Stock	6,924	$20.15	$139,518.60	Disclosure SEC source: 0001125345-19-000018 · wf-form4_154966566940123.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 19, 2018 Filed Oct 19, 2018 20:24 UTC	Dermira, Inc. DERM · Entity 11896	SaleCommon Stock	4,000	$13.75	$55,000.00	Disclosure SEC source: 0001562180-18-004253 · primarydocument.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,051 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document
June 19, 2018 Filed Jun 20, 2018 22:07 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $80.69	$0.00	Disclosure SEC source: 0001209191-18-038852 · doc4.xml · derivative · entry 2 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-06-19 F2 · derivative.exercise_date: The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 19, 2019. Read SEC document
June 19, 2018 Filed Jun 20, 2018 22:07 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001209191-18-038852 · doc4.xml · nonDerivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,750 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 19, 2019. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.